Handelsbanken Fonder’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $817M | Sell |
680,927
-27,617
| -4% | -$28.2M | 2.33% | 8 |
|
|
2026
Q1 | $652M | Sell |
708,544
-56,238
| -7% | -$57M | 2.17% | 8 |
|
|
2025
Q4 | $822M | Sell |
764,782
-87,727
| -10% | -$83.9M | 2.48% | 8 |
|
|
2025
Q3 | $650M | Buy |
852,509
+92,689
| +12% | +$69M | 2.07% | 8 |
|
|
2025
Q2 | $592M | Buy |
759,820
+25,944
| +4% | +$20.2M | 2.1% | 6 |
|
|
2025
Q1 | $606M | Sell |
733,876
-31,174
| -4% | -$25.9M | 2.5% | 4 |
|
|
2024
Q4 | $591M | Sell |
765,050
-1,975
| -0.3% | -$1.64M | 2.25% | 6 |
|
|
2024
Q3 | $680M | Buy |
767,025
+8,926
| +1% | +$8.02M | 2.69% | 4 |
|
|
2024
Q2 | $686M | Sell |
758,099
-37,511
| -5% | -$30M | 2.98% | 4 |
|
|
2024
Q1 | $619M | Sell |
795,610
-41,638
| -5% | -$29.6M | 2.66% | 4 |
|
|
2023
Q4 | $488M | Sell |
837,248
-12,962
| -2% | -$7.57M | 2.37% | 4 |
|
|
2023
Q3 | $457M | Sell |
850,210
-73,738
| -8% | -$38M | 2.56% | 4 |
|
|
2023
Q2 | $433M | Buy |
923,948
+17,514
| +2% | +$7.34M | 2.32% | 4 |
|
|
2023
Q1 | $311M | Buy |
906,434
+56,444
| +7% | +$19M | 1.8% | 5 |
|
|
2022
Q4 | $311M | Buy |
849,990
+23,585
| +3% | +$8.36M | 1.95% | 4 |
|
|
2022
Q3 | $267M | Sell |
826,405
-27,957
| -3% | -$8.86M | 1.79% | 4 |
|
|
2022
Q2 | $277M | Sell |
854,362
-57,965
| -6% | -$17.4M | 1.8% | 4 |
|
|
2022
Q1 | $261M | Sell |
912,327
-131,549
| -13% | -$33.9M | 1.46% | 8 |
|
|
2021
Q4 | $288M | Sell |
1,043,876
-4,344
| -0.4% | -$1.1M | 1.42% | 8 |
|
|
2021
Q3 | $242M | Buy |
1,048,220
+28,132
| +3% | +$6.94M | 1.27% | 10 |
|
|
2021
Q2 | $234M | Buy |
1,020,088
+24,300
| +2% | +$4.88M | 1.22% | 10 |
|
|
2021
Q1 | $186M | Sell |
995,788
-44,906
| -4% | -$8.78M | 1.06% | 14 |
|
|
2020
Q4 | $176M | Buy |
1,040,694
+49,503
| +5% | +$7.39M | 1.07% | 12 |
|
|
2020
Q3 | $147M | Buy |
991,191
+71,323
| +8% | +$11M | 1.07% | 15 |
|
|
2020
Q2 | $151M | Buy |
919,868
+111,396
| +14% | +$17.1M | 1.27% | 10 |
|
|
2020
Q1 | $112M | Sell |
808,472
-102,997
| -11% | -$14.2M | 2.41% | 5 |
|
|
2019
Q4 | $120M | Buy |
911,469
+24,983
| +3% | +$2.9M | 2.07% | 6 |
|
|
2019
Q3 | $99.1M | Buy |
886,486
+100,000
| +13% | +$11.1M | 2% | 9 |
|
|
2019
Q2 | $87.1M | Buy |
786,486
+197,076
| +33% | +$23.2M | 1.61% | 14 |
|
|
2019
Q1 | $76.5M | Buy |
589,410
+216,276
| +58% | +$26.3M | 1.48% | 19 |
|
|
2018
Q4 | $43.2M | Buy |
373,134
+12,994
| +4% | +$1.45M | 0.87% | 39 |
|
|
2018
Q3 | $38.6M | Buy |
360,140
+46,000
| +15% | +$4.6M | 0.73% | 47 |
|
|
2018
Q2 | $26.8M | Hold |
314,140
| – | – | 0.53% | 61 |
|
|
2018
Q1 | $24.3M | Buy |
314,140
+5,000
| +2% | +$403K | 0.48% | 65 |
|
|
2017
Q4 | $26.1M | Buy |
309,140
+8,200
| +3% | +$698K | 0.57% | 53 |
|
|
2017
Q3 | $25.7M | Sell |
300,940
-22,000
| -7% | -$1.8M | 0.6% | 53 |
|
|
2017
Q2 | $26.6M | Buy |
322,940
+55,000
| +21% | +$4.49M | 0.68% | 51 |
|
|
2017
Q1 | $22.5M | Buy |
267,940
+20,000
| +8% | +$1.6M | 0.63% | 58 |
|
|
2016
Q4 | $18.2M | Buy |
247,940
+6,000
| +2% | +$447K | 0.56% | 69 |
|
|
2016
Q3 | $19.4M | Sell |
241,940
-4,127
| -2% | -$330K | 0.57% | 70 |
|
|
2016
Q2 | $19.4M | Hold |
246,067
| – | – | 0.79% | 52 |
|
|
2016
Q1 | $17.7M | Sell |
246,067
-111,435
| -31% | -$8.43M | 0.76% | 51 |
|
|
2015
Q4 | $30.1M | Buy |
+357,502
| New | +$29.7M | 0.58% | 49 |
|
Other funds holding LLY
SC
ONB
GIM
WAM
CRM
VNIM
CNB
Handelsbanken Fonder's LLY Position: Q2 2026 in Review
Handelsbanken Fonder reduced its Eli Lilly (LLY) stake by 3.9% in Q2 2026, selling an estimated $28.2M and leaving 680,927 shares worth $817M. The position accounts for 2.33% of the portfolio, ranked #8.
Handelsbanken Fonder first reported a position in LLY in Q4 2015 and has held it in 43 quarters since. The position peaked at $822M in Q4 2025. 922 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Handelsbanken Fonder held 680,927 shares of Eli Lilly worth $817M as of Q2 2026.
- Handelsbanken Fonder sold 27,617 Eli Lilly shares in Q2 2026, an estimated $28.2M.
- Eli Lilly made up 2.33% of Handelsbanken Fonder's portfolio in Q2 2026, its #8 holding.
- Handelsbanken Fonder first reported a position in Eli Lilly in Q4 2015 and has held it in 43 quarters since.
- Handelsbanken Fonder's Eli Lilly position peaked at $822M in Q4 2025.
- 922 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.